CytoDyn announces productive pre-BLA meeting with FDA for PRO 140 combination therapy
CytoDyn announces that it had a productive meeting with the FDA regarding the Company’s planned BLA. Based on FDA feedback, the Company will continue to gather safety and efficacy data from its ongoing monotherapy HIV clinical trials to support the BLA submission. June 22, 2018